Genetic variation at the IL1RAP locus and its influence on late-life by Mårdensjö, David
               THE SAHLGRENSKA ACADEMY 
 
 
 
 
 
 
 
Genetic variation at the IL1RAP locus and its influence on late-life 
depression in a population-based sample in Gothenburg, Sweden. 
 
 
Degree Project in Medicine 
 
David Mårdensjö 
 
Programme in Medicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gothenburg, Sweden 2017 
 
 
Supervisor: Anna Zettergren, Ph.D 
 
Department of Psychiatry and Neurochemistry 
Institute of Neuroscience and Physiology 
Sahlgrenska Academy, University of Gothenburg 
 
Abstract
Degree Project, Programme in Medicine
Title: Genetic variation at the IL1RAP locus and its influence on late-life depression in a population-based sample in
Gothenburg, Sweden
Author: David Mårdensjö
Department of Psychiatry and Neurochemistry at Institute of Neuroscience and Physiology, Sahlgrenska Academy,
University of Gothenburg
Gothenburg, Sweden, 2017
Introduction: Recently, it was discovered in two large genome-wide association studies that there
is an association between genetic variation in the gene interleukin-1 receptor associated protein
(IL1RAP) and Alzheimer’s disease traits. Inflammation has been implicated as an important path-
omechanism for both dementia and late-life depression (LLD). However, the association between
ILRAP and LLD have to our knowledge never been specifically investigated
Aim: The aim of this study was to examine the possible association between LLD and genetic
variation in, or in close vicinity, to the gene IL1RAP in a population-based sample of older indi-
viduals.
Methods: Genotype data were available for 3,559 study participants from four cohorts of the lon-
gitudinal gerontological and geriatric population studies in Gothenburg, and 2715 were included
in the statistical analysis after exclusion. All participants took part in a neuropsychiatric and neu-
ropsychological examination. The relation between genotype and depression diagnoses as well as
with the severity of depressive symptoms (measured with MADRS-score) were investigated.
Results: The main findings were associations between the common homozygotes of rs3773976,
rs12053868, rs3773970 and rs4687151, and females with major depression, with the strongest
being for rs3773970 (OR: 2.01 [95% CI: 1.14-3.56], p=0.016) in the logistic regression model ad-
justed for APO ε4-status and age at first interview. Significant associations between the common
homozygotes of two of these polymorphisms (rs3773976 and rs3773970) and increased MADRS-
score were also found in the linear regression model using the same covariates. No association
was found for rs9877502.
Conclusions: Our results indicate that genetic variation at the ILRAP locus may be of importance
for LLD. However, the effect size and study sample were small. The finding should be interpreted
with caution until replicated in additional samples of older indviduals.
Key words: Late-life depression, gene, interleukin 1 receptor accessory protein
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1 Introduction
1.1 Depression and late-life depression
Depression is a gruesome illness, first and foremost for the affected one but also for friends and
relatives of the affected. The life time risk in the western world is expected to be between 9-19%,
with women being more affected than men [1–3]. Measured in disability-adjusted-life-year (DALY),
unipolar depression places itself at third place worldwide before diseases as ischemic heart dis-
ease and HIV/AIDS, according to the WHO[4]. Depression is a growing concern in the industrial
part of the world, partly because it increases the all-cause mortality[5], and partly because of the
huge economic burden it causes for society[6].
American Psychiatric Association has published the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM) that sets up criteria for the classification of mental illnesses and it is widely
used internationally. Major depression is diagnosed based on nine criteria. At least one of the two
core criteria (depressed mood and lack of interest) has to be present with at least four of the ad-
ditional criteria (weight loss, insomnia or hypersomnia, psychomotor agitation or retardation, fa-
tigue, feelings of guilt or worthlessness, diminished ability to concentrate and recurrent thoughts
about death or suicidal thoughts)[7]. Minor depression can be diagnosed when the patient exhibits
at least two, but less than five, of the criteria[7]. The classification of depression is a controversial
area, and other classifications have been proposed because of the heterogeneous clinical picture
the disease exhibits[8].
It is argued that the clinical symptoms differ between depression with a first debut later in life and
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early onset depression (EOD)[9]. Although there is no strict classification for late-life depres-
sion (LLD) it is usually said to be depression with a debut after 50-65 years of age. DSM-V does
not take age of onset into consideration[7]. LLD is usually more associated with a cognitive and
executive decline while EOD is associated with more emotional symptoms[9, 10]. Melancholic
depression and psychomotor disturbances in depressed individuals seem to increase with age[11].
Major depression is quite uncommon in the older population (5%) even though many older peo-
ple exhibits depressive symptoms (27%)[12]. Whether the incidence for depression change with
age is still unclear[12]. Depressive symptoms in late-life are associated with psychological dis-
tress, decreased executive functions and lower life satisfaction[13]. LLD increases the all-cause
mortality, especially among men[14]. In addition, suicide rates increase with old age[15], with
depression being the strongest risk factor followed by other mental disorders and chronic somatic
diseases[16]. Multi-morbid individuals, with diseases such as diabetes and cardiovascular insults,
are also more likely to suffer from depression[17–19].
1.2 Genetic research
1.2.1 History and genetic research in general
Since its entrance, in the seventies, genetic research has given us tremendous amounts of new in-
formation and increased our understanding of disease and its causes. Monogenic disorders, like
Huntington’s disease, have been fully characterized and our understanding of them have increased
tremendously[20]. Important knowledge has also been gained for multifactorial diseases, albeit
with varying results.
Genetics can only in limited extent explain why certain individuals develop mental illnesses. A
disease like schizophrenia is usually considered to have a strong genetic factor, compared to other
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mental disorders, but in a famous Finnish adoption study with children born by mothers with
schizophrenia it was shown that a healthy home environment is protective against the development
of psychotic symptoms[21]. The same is true for depression where certain genes can predispose
and set a lower threshold for developing depression - but it still requires that the individual is ex-
posed to a certain number of negative life events[22].
Genetic polymorphism
The human genome is built up on roughly around three billion base pairs[23]. It is remarkably
consistent over time and all humans share most of the genetic information. It is usually estimated
that only about 0.5 % of the DNA vary between people[24]. The loci of variation are called alle-
les. Alleles occurring less than < 1 % in the population are regarded as mutations, while alleles
occurring > 1 % are regarded as variants or polymorphisms[25].
Point mutations in the human genome can be caused by insertions, deletions and substitutions. A
substitution occurring > 1 % in the population is also called a single-nucleotide polymorphism
(SNP). SNPs are the most frequent variant in the human genome. SNPs tend to occur more fre-
quently in non-coding regions, but they can still have an effect on the phenotype through tran-
scriptional regulation and gene splicing. SNPs in coding regions can either be synonymous, lead-
ing to the same protein, or non-synonymous and coding for a different amino acid or a stop codon.
Deletions or insertions in coding regions will change the reading frame and are often deleteri-
ous. Some SNPs affect human phenotype and predispose certain diseases. However, most have no
known effect.[25, 26]
New SNPs are continuously discovered and up to date have millions been found. Each individual
SNP gets a unique identifier, the so called “rsID”. Several databases have been constructed to keep
track of all the SNPs. One of the most used one is the Single Nucleotide Polymorphism database
(dbSNP: www.ncbi.hlm.nih.gov/SNP), where the records are updated every 1-2 months with new
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SNPs.
There is also extensive structural variation in the genome which constitutes of inversions, translo-
cations and copy number variants (CNVs). CNVs are variations in the number of copies of quite
long DNA-stretches (>1 kb) caused by either duplications or deletions[25]. These structural vari-
ants affect human phenotype and in some extent cause human disease[25]. Unfortunately it has
been hard to study structural variation in relation to human disease until recently[27]. With the in-
creasing use and advances in microarray techniques and next-generation sequencing, it have been
made possible to study CNVs further and new important findings have been discovered for some
complex trait diseases such as autism[28]. Two additional polymorphisms are the repeats: short
tandem repeats (STRs) and variable number of tandem repeats (VNTRs), where a short strand of
DNA are repeated several times (2-13 nucleotide sequence for STRs and 10-100 nucleotide se-
quence for VNTRs)[29].
Linkage analysis and population based methods
Even though some genetic variants do not have any known effect, they can still serve as excellent
markers for genetic research if they are located close to the region of interest. During meiosis and
recombination, genes far away from each other tend to separate, while nearby regions are more
likely to be inherited together - they are said to be in high linkage disequilibrium. This biological
phenomenon lays the foundation for linkage studies and population-based studies.[26]
Linkage analysis dominated in the 1990s when much of the research was aimed at studying af-
fected families with Mendelian disorders like cystic fibrosis and Huntington’s disease[26]. Even
though linkage analysis can be used for multifactorial diseases it is not preferred for studying
complex trait diseases because it is hard to reach enough power[30]. Rather than using SNPs
are the STRs more well suited for linkage analysis because of their high rate of variability and
because they are multiallelic (in comparison with SNPs which are biallelic)[31]. This is an ad-
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vantage when studying rare family clustered monogenic disorders[26]. About 300-400 STRs are
required for conducting a linkage analysis[32].
Attempts to use linkage analysis when examining complex trait diseases, such as diabetes and
mental disorders, have proved disappointing because of the small effect each gene contributes to
the disease[30]. Finding an association between a genetic variant and a complex trait disease re-
quire larger samples which make population-based association studies a better choice[26]. Due to
the STRs high variance[31], which risk to confound a large association study, will SNPs be more
suitable because they are more stable over many generations and more plenteous than STRs[26].
Candidate gene association studies requires a prior hypothesis based on earlier research and find-
ings, which is a limiting factor when studying complex trait diseases comprising of thousands
of causative genes. Nevertheless, the candidate gene approach can be a decent tool to detect any
effect when studying a rare allele or when having a rather small study sample. Markers are then
chosen close to the candidate gene, which usually are SNPs. The SNPs can either be used as sur-
rogate markers, i.e. they are in linkage disequilibrium with the region of interest, or they can be
direct cause of the disease.[26, 33]
Linkage analysis and candidate gene association studies can in certain cases also be used in com-
bination. Linkage analysis can first be used to find interesting regions in affected families and this
information can then be extended to the whole affected population[26]. This approach was ap-
plied when APO ε4 and its role in Alzheimer’s disease (AD) was established[34, 35].
Genome-Wide Association studies (GWASs) have made it possible to scan the entire genome
for risk factors for complex trait diseases without a prior hypothesis. With the completion of the
HapMap project (HapMap: https://www.genome.gov/10001688/international-hapmap-project/),
researchers had sufficient number of SNPs for conducting GWASs. Thousands of SNPs are re-
quired for conducting a GWAS. Because of multiple testing there is a high risk for false positives.
This problem requires sufficient statistical correction for multiple testing. GWASs has provided
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us with vast new information, but caution should be taken before making too big inferences since
the enormous data that are given can be hard to interpret and put in a biological perspective. A
GWAS with a positive association should be followed by fine mapping of the region and repli-
cation in an independent population. Consequently, GWASs can give us new clues and point us
in the right direction, but further studies are required before we can make any inferences of the
result.[36]
1.2.2 Neurobiology and genetics in relation to depression and late-life depres-
sion
It has been shown that depression tends to aggregate in families and that the heritability is ex-
pected to be up to 37-38 % [37, 38]. Many genetic risk factors have been found but they have
been hard to replicate (even in the largest of GWASs), and their significance remains disputed[39].
The most likely explanation for this is that the studies have been under-powered[40]. A GWAS
of depression usually requires tens of thousands participants[40]. Another possible explanation
is that former studies have used a too heterogeneous study sample. Indeed, depression is a highly
heterogeneous disease with different main symptoms, recurrence rates, age of debut, response to
treatment etc.[41], hence could it be plausible to assume that the genetic background will differ
between depressed individuals.
Monoamine hypothesis
Trying to solve the enigma of depression took off more than 60 years ago when the first effective
antidepressants were discovered. With the discovery of Imipramine (tricyclic agent) and Ipro-
niazid (monoamine oxidase inhibitor), and the surprising finding that they had beneficial effects
in depressed individuals[42, 43], comprehensive research was initiated that would last several
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decades in an attempt trying to understand the mechanisms behind these drugs, and through that
understand the pathogenesis of depression. Today we know that these medications, as well as the
newer antidepressants, work by immediately affecting the levels of serotonin, norepinephrine and
in little extent dopamine. Famous hypothesis about these neurotransmitters were proposed during
the 60s by Schildkraut (catecholeamine hypothesis)[44] and Coppen (serotonin hypothesis)[45].
Serotonin levels plays a vital role in certain depressed individuals, which have been shown through
tryptophan-depletion studies and PET-studies[46, 47]. Several susceptibility genes have been
found that codes for serotonin transporter (SLC6A4), the serotonin receptors (HTR1A and HTR2A)
and enzymes involved in degradation of monoamines (MAO) [48–52]. These genes and the gene
for the norepinephrine transporter (SLC6A2) have also shown to affect the outcome of treatment
with antidepressants[53–55]. The brain specific isoform of Tryptophan hydroxylase (TPH2) has
also been implicated as a susceptibility gene[56], as well as genes involved in dopamine neuro-
transmission; dopamine D4 receptor (DRD4) and dopamine active transporter 1 (DAT1/SLC6A4)[57,
58].
However, it is a very simplistic view that depression should be caused only by a disturbance in the
neurotransmitters: Firstly, even though the conventional antidepressants targeting the serotonergic
neurotransmission change the levels of neurotransmitters immediately, they do not have a clinical
effect until after up to 2-3 weeks[59], which indicates other mechanisms of action (i.e. changes
in neuroplasticity and neurogenesis[60, 61]). Secondly, antidepressants can be used for several
other conditions, distant from depression, like neuropathic pain and eating disorders[62]. Thirdly,
not all individuals respond to therapy targeting the serotonergic neurotransmission, and there are
several drugs not targeting the serotonergic neurotransmission for treating depression[63]. Nev-
ertheless, serotonergic neurotransmission, and norepinephrine neurotransmission to some extent,
keeps being a hot topic and generating articles. However, during recent years the scientific field
has been shifting towards other pathways involved in the intricate pathogenesis of depression.
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Hypothalamic–pituitary–adrenal (HPA) axis hypothesis
In the first quarter of the 20th century, it was discovered that depressed individuals have elevated
levels of stress hormones[64]. Several published articles have shown that depressed individuals
exhibits a hyperactive HPA-axis with elevated levels of Corticotropin-releasing hormone (CRH),
cortisol and a reduced sensitivity for feedback inhibition[65–67]. It is believed that the hypercorti-
solemia seen in depression contributes to hippocampal atrophy, insulin resistance and weight gain
in certain depressed individuals[68, 69]. Whether a deranged HPA-axis causes depression, or if
it is just an epiphenomenal to depression itself, has been widely debated. However, studies have
shown that people with trauma in their childhood, like sexual or physical abuse, are more likely to
have a hyperactive HPA-axis, even if they are not currently depressed[70]. It has also been shown
in rodents that maternal behavior affects DNA methylation pattern in glucocorticoid receptor and
the ability to cope with stress in their offspring[71], and long-term antidepressant treatment seems
to normalize the hyperactive HPA-axis[72]. Genetic variation in the glucocorticoid receptor also
seems to affect treatment outcome with antidepressants[55].
Neurogenesis and neurotrophic factors
Reduced volume of the hippocampus and several structures in the prefrontal cortex are often
seen in depressed individuals[68, 73, 74]. This could partly be explained by hypercortisolemia,
as earlier mentioned, by inhibiting neurogenesis and causing neurotoxicity[75, 76]. However,
other mechanisms of action have been proposed for this phenomenon, and brain-derived neu-
rotrophic factor (BDNF) has gained a lot of interest. BDNF is important for neuronal integrity
and neurogenesis[77–79]. Preclinical trials have shown that the BDNF concentration decreases
in rodents exposed to chronic stress[80], and that antidepressant treatment can increase BNDF
concentration[81]. BDNF directly infused into rodents hippocampus also have an antidepres-
sant effect[82]. These results have also been replicated in human subjects through post-mortem
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studies[83], as well as by studying living individuals by measuring serum BDNF[84]. However,
the BDNF-hypothesis may need to be revalued because other studies have shown more or less the
opposite effect of BDNF regarding depression[85, 86].
The Val66Met polymorphism in the BDNF gene, which has been implicated in many disorders,
have been examined through candidate gene studies of depression but the results have been mixed
and inconsistent[87, 88].
Inflammation and depression
Inflammation and its relation with depression has gained a lot of interest. Cytokines and other
inflammatory proteins are often elevated during a depressive episode [89], and individuals admin-
istered Interferon, the main treatment for hepatitis C, suffer from mood alterations[90, 91].The
inflammatory response affects both monoaminergic neurotransmission and the HPA-axis, two
pathways implicated in the pathogenesis of depression[92, 93]. It is theorized that the interplay
between depression and inflammation is a remnant from past times where stress or a potential
threat would mount an inflammatory response in case of serious injury or infection. However, this
response could be redundant and quite otiose in a modern society full of low threat stressors[94].
Anti-inflammatory drugs have shown promising results treating depression[95]. In addition, the
common SSRI antidepressant also have an anti-inflammatory effect[96].
Genetic variations in the inflammatory mediators and their association with depression have been
studied thoroughly, whereof a handful have been replicated in numerous studies, albeit some-
times with inconsistent results[97]. They include the cytokines IL-1β[98–100], IL-6[100, 101],
IL-10[102, 103] and TNF-α[104–106]; the chemokine MCP1/CCL2[107]; the acute phase reactant
CRP[108, 109] and Phospholipase A2 enzyme, PLA2G4A[110, 111].
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Genes specifically implicated for late-life depression
LLD has not been studied in the same extent as EOD and the heritability is estimated to be lower[112],
hence have the findings been modest. However, there is evidence that implicates that there could
be an etiological difference between EOD and LLD[113]
Depressed older individuals often exhibit white matter lesions in the brain[114], hence has the
term “vascular depression” been coined[115]. Much of the focus has been aimed at studying ge-
netic variants in genes that could conduce vascular lesions. APOE ε4 has long been a hot candi-
date in LLD but the results have been inconsistent[116–118].
5-10-methylenetetrahydrofolate reductase (MTHFR) is the rate determining step for the methy-
lation cycle and thus crucial for DNA-structure and building amino acids. The methylation cycle
requires folic acid and cobalamins as substrates. It is common practice to examine folic acid and
cobalamins in depressed individuals, especially among the older population, since both folic acid
and cobalamins are often decreased during depression and affect treatment outcome[119, 120].
Genetic variation in the MTHFR gene are also known for increasing the risk for vascular events
through elevated homocystein levels[121], and an association was found between the C677T poly-
morphism and depression in one study[122]. However, a meta-analysis of five studies did not find
any association[116].
Most of the candidate gene association studies have yielded inconsistent results. However, the
largest meta-analysis of LLD up-to-date found modestly significant associations for APOE, BDNF
and SLC6A4. These results differ slightly from meta-analysis conducted for EOD, which suggests
different mechanisms of action.[116]
Interestingly, one of the largest GWASs of depression with 34,549 participants, with a mean age
of 66.5 years, only found one significant association in the 5q21 region - a gene desert area[123].
This example illustrates clearly that genetic research for depression have methodological prob-
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lems, where significant results from candidate gene associations studies and meta-analysis hardly
never have been replicated in a GWAS. However, two genes have been found through GWASs and
survived replication in further studies: bicaudal C homologue gene 1 (BICC1) and piccolo presy-
naptic cytomatrix protein (PCLO)[124] Both genes are expressed widely in the brain and are im-
portant for synaptic connections and cell-to-cell communication[125, 126].
1.3 Depression and dementia - a shared pathogenesis?
It is well known clinically that depression and dementia are somehow intertwined and can be hard
to distinguish from one another in the older population. Individuals suffering from depression,
both in early- and late-life, are at an increased risk of developing dementia, and it seems that there
is a dose-response effect in this relation where number of depressive episodes, duration and sever-
ity further increase the risk[127]. About 50 % of individuals suffering from LLD have a cogni-
tive impairment[128], and even if the depression goes into remission many older individuals still
have residual cognitive impairment[129]. On the other hand, individuals diagnosed with mild
cognitive impairment (MCI) or dementia are more likely to develop depression[130, 131]. De-
pression could be an independent risk factor for developing dementia[127], but LLD could also
be the first manifestations of a merging MCI and dementia, i.e. depression could be a prodromal
symptom[127, 132].
The relationship, and the underlying mechanisms, between depression and MCI/dementia have
generated many hypotheses. First there is the obvious one that individuals that start to develop
cognitive difficulties get depressed just because of that. They may no longer be able to partici-
pate in social events and activities they once enjoyed and this cause withdrawal and apathy which
could trigger or aggravate a depression.[133]
Another hypothesis comes from that depression goes with hypercortisolemia[65, 66], and reduced
12
levels of BDNF[84] which causes hippocampal atrophy[68]and structural changes in other parts
of the brain as well[73, 74]. This could cause a mild but stable MCI in people with a low cogni-
tive reserve that would wear off with antidepressant treatment, or it could cause earlier symptoms
in individuals with a preclinical dementia that otherwise may have stayed undetected[134].
Cerebrovascular disease can cause, aggravate and maintain depression[114], hence the term “vas-
cular depression”[115], and depression itself is a risk factor for cerebrovascular events[135]. Con-
sequently, it is believed that this could be one of the mechanisms linking LLD and dementia (vas-
cular dementia in particular[136], but cerebrovascular disease has also shown to contribute to
AD[137]). Genetic research in evidence for this include, as aforementioned, genetic variation in
APOE ε4 which is associated with AD[138] and depression in some studies, albeit the results have
been conflicting about the latter association[116–118]. Another gene that has been studied is the
ACE gene which encodes the angiotensin converting enzyme. Genetic variation in the ACE gene
have been associated with both depression and dementia[139].
Even though disturbances in the serotonergic neurotransmission mostly have been studied in re-
lation to depression, there is some merging evidence linking serotonergic disturbances and AD.
Healthy individuals treated with SSRI exhibit reduced levels of Aβ in the CSF, and AD mouse
models treated with SSRI exhibits less Aβ in brain interstitial fluid and less senile plaque formation[140].
Chronic SSRI treatment has also shown to increase neurogenesis and protect cells against the cy-
totoxic effect of the Aβ-peptides[141]. One possible mechanism explaining this connection could
be that there seems to be a relation between activity in the serotonin receptors and amyloid pre-
cursor protein metabolism[142, 143]. However, there is a lack of evidence for treating demented
individuals with antidepressants solely for preventing disease progress in their dementia[144].
The most appealing hypothesis would be that certain types of LLD, MCI and dementia are all part
of the same spectrum with the same underlying neurodegenerative mechanisms[132], but more
neurobiological and genetic research have to be done before making such an assumption. How-
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ever, there is some evidence that LLD share some of the neurodegenerative features that charac-
terizes dementia. Individuals with a typical AD CSF-profile and increased uptake on a Pittsburgh
Compound B Uptake Measurement (reflecting amyloid burden), in otherwise cognitive normal
adults, are more likely to suffer from depression or develop depression and mood changes over
time, suggesting that depression is prodromal symptom in AD for certain subtypes[145, 146].
As aforementioned, depression can cause a low grade inflammation in the periphery and cen-
tral nervous system[89, 147]. Emerging evidence shows that is the case for AD as well. The fo-
cus has long been aimed at studying the senile plaques and neurofibrillary tangles which are the
hallmarks of the disease[148]. Mutations in the genes encoding amyloid precursor protein and
presenilin proteins have been found for familial forms of AD[149, 150], which gave the “amy-
loid hypothesis” further viability[151]. However, these results have been hard to extrapolate to
the large population consisting of late-debut spontaneous AD. Instead has neuroinflammation
been proposed as a crucial mechanism for AD development[152]. Indeed, individuals with AD
exhibit very much the same neuroinflammatory picture as depressed individuals with increased
neuroinflammation[153] and increased levels of cytokines in CSF and serum[154]. Cytokine lev-
els are also increased further in individuals with AD that also suffer from depression[155]. In ad-
dition, genetic variation in inflammatory genes, IL-1β and TNF-α, have been associated with both
AD[156, 157], and depression [98–100, 104–106].
It is now well established that both depression and AD involves neuroinflammation. Whether this
is a secondary phenomenon or a pivotal mechanism is still unclear. However, multiple hypothe-
ses about how neuroinflammation could contribute to respective disease, with a joint mechanism,
have been proposed. Firstly, TNF-α correlates negatively with insulin-like growth factor 1 (IGF-1)
in individuals with AD, suggesting that inflammation can lead to decreased levels of IGF-1[158].
IGF-1 is vital for neuronal integrity, normal brain development and for an efficient Aβ-clearence
in the brain[159]. Lowered levels of IGF-1 are associated with AD[160] while higher levels prob-
ably are protective[161]. Similar correlations have been found for depression[162, 163]. Another
14
factor that decreases when subjected to neuroinflammation is the neurotrophic factor BDNF[164],
which has been described earlier. Both depression [83, 84] and AD[165, 166] (and several other
neurodegenerative diseases[167]) goes with decreased levels of BDNF. Lastly, a mechanism that
is worth mentioning: Inflammation induce the enzyme indolamine-2,3-dioxygenase (IDO) and
this enhances the metabolism of tryptophan to kynurenine. Tryptophan is the substrate for pro-
ducing serotonin and hence could this enzyme induction cause serotonin depletion which could
cause depressive symptoms[168]. In addition, the metabolite of kynurenine, 3-hydroxykynurenine,
is neurotoxic and could contribute to the cognitive impairments seen in depression and AD[169,
170].
1.3.1 Specific background for conducting this study
In a recent longitudinal GWAS studying amyloid accumulation using F-florbetapir PET a strong
association was found between the SNP rs12053868, located in the gene Interleukin-1 receptor
associated protein (IL1RAP), and accelerated amyloid accumulation. This SNP was also asso-
ciated with an increased cognitive decline, greater temporal cortex atrophy and decreased mi-
croglial activity. Deep sequencing of the IL1RAP gene revealed that six additional SNPs in the
gene are associated with an increased amyloid burden. The authors suggest that microglial ac-
tivity and the IL1/IL1RAP signaling pathway are vital for preventing amyloid accumulation and
progression into AD.[171]
In another GWAS studying AD biomarkers in CSF the SNP rs9877502 was found to be associ-
ated with increased CSF tau and p-tau levels as well as accelerated cognitive decline and risk for
developing AD. The SNP rs9877502 is located close to the non-coding RNA gene SNAR-1, but
in close proximity lies several other genes widely expressed in the brain including IL1RAP. In a
subsequent gene expression analysis it was also shown that rs9877502 is associated with IL1RAP
expression in the brain[172].
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IL1RAP constitutes a vital part of the IL1-receptor which binds the cytokine IL1 which in turn
take part in offsetting the inflammatory response during infection and trauma[173]. As earlier de-
scribed, neuroinflammation has been implicated as a crucial mechanism in the pathogenesis of de-
pression and AD. Genetic variation in the IL1β gene have been associated with both diseases[98–
100, 157]. However, variation in the IL1RAP gene and the nearby SNP rs9877502 have to our
knowledge never been specifically studied in relation to depression. Since depression and demen-
tia are believed to share certain risk factors and pathomechanisms, as previously described, it now
seems plausible to examine the aforementioned SNPs in relation to LLD.
1.4 Aim
The aim of this study was to examine the possible association between five SNPs in, or in close
vicinity, to the IL1RAP locus (rs3773976, rs12053868, rs3773970, rs4687151 and rs9877502)
and late-life depression in a population-based sample of older individuals, by investigating the
relation between genotype and disease status as well as with the severity of depressive symptoms
(measured using MADRS-score).
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2 Methods and materials
2.1 Study population
The population of this study consists of 3559 participants from four different cohorts (PPSW-H70,
H85, H95+ and H70 born 1944) of the longitudinal gerontological and geriatric population studies
in Gothenburg. Participants have been collected from the Swedish population register based on
birth dates.
Prospective Population Study of Women in Gothenburg (PPSW) and H70 born
1930
The PPSW is a prospective longitudinal and multidisciplinary study of women in Gothenburg
born 1908, 1914, 1918, 1922 and 1930 on specific dates (6, 12, 18, 24 and 30). 1594 individuals
were invited and 1462 agreed to participate (response rate = 91.7%) when the study commenced
in 1968. The study has been described elsewhere[174]. Follow-up examinations have been done
seven times since then, most recently in 2015.[175, 176]
The H70-study commenced in 1971 with participants born in 1901. The aim of the study was to
study the normal aging process in both genders. New cohorts with 70-year olds have been added
numerous times through the years. So far, there have been five cohorts whereof two have been
studied longitudinally (1901-02 and 1930). The H70 cohort born in 1930, which is the one in-
cluded in this study, has been described elsewhere[177, 178]. Participants born on specific dates
17
between January 1, 1930 and December 31, 1930 on specific dates (6, 12, 18, 24 and 30) and liv-
ing in Gothenburg area were invited to participate. 1287 individuals were invited and 827 agreed
to participate (response rate = 64%).[175, 176, 179]
PPSW and H70 born in 1930 were merged into one cohort in 2000. This cohort consists of women
born in 1914, 1918, 1922 and 1930, and men born in 1930. Women born in 1908 were added to
the H95+ cohort (see further below) because of low number of participants. Since 2000 have new
participants been recruited to the merged PPSW-H70 cohort.[175, 176]
The number of participants from the PPSW-H70 cohort, where genotyping has been done, is
shown in Table 1. Reasons for not being genotyped include: death, non-interest, relocated from
Gothenburg or unable to get in contact.
Table 1: Participants from PPSW-H70
Year of birth Women (n) Men (n) Total (n)
1914 43 0 43
1918 177 0 177
1922 223 0 223
1930 567 402 969
Total 1010 402 1412
H85
The H85 cohort is a mixed gender cohort of participants born in 1923-24 that commenced in 2009
with follow-ups in 2011 and 2013. The cohort has been described elsewhere[177]. Every second
85-year old born between July 1, 1923 and June 30, 1924 and living in Gothenburg area were in-
vited to participate. 944 individuals were invited and 571 agreed to participate (response rate =
60.5%).[176]
The number of participants from the H85, where genotyping has been done, is shown in Table
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2. Reasons for not being genotyped include: death, non-interest, relocated from Gothenburg or
unable to get in contact.
Table 2: Participants from H85
Year of birth Women (n) Men (n) Total (n)
1923 167 104 271
1924 151 95 246
Total 318 199 517
H95+
The H95+ cohort study started in 1996 and is probably the largest study in the world of men-
tal disorders in people older than 95 years. The cohort has been described elsewhere[180]. In
1996-1998, all 95-year olds, born between July 1, 1901 and December 31, 1903 and living in
Gothenburg area were invited to participate. 521 individuals were invited initially and 338 agreed
to participate (response rate = 65%). Over time have more 95-year olds been recruited to the
cohort.[176]
The number of participants from the H95+ cohort, where genotyping has been done, is shown in
Table 3. Reasons for not being genotyped include: death, non-interest, relocated from Gothenburg
or unable to get in contact.
19
Table 3: Participants from H95+
Year of birth Women (n) Men (n) Total (n)
1901 2 0 2
1902 7 1 8
1903 23 6 29
1904 31 5 36
1905 37 6 43
1906 66 14 80
1907 71 17 88
1908 71 18 89
1909 59 13 72
1910 13 4 17
1911 8 3 11
Total 388 87 475
H70 born 1944
The H70 cohort consists of mixed-gender participants born in 1944 and the cohort was assem-
bled in 2014. Every 70-year old born on specific birth dates (dates ending with 0, 2, 5 and 8) be-
tween January 1, and December 31, 1944 and living in Gothenburg area were invited to partici-
pate. 1666 individuals were invited and 1203 agreed to participate (response rate = 72.2%). So
far, no data from this study has been published.[176]
The number of participants from the H70, where genotyping has been done, is shown in Table
4. Reasons for not being genotyped include: death, non-interest, relocated from Gothenburg or
unable to get in contact.
Table 4: Participants from H70
Year of birth Women (n) Men (n) Total (n)
1944 610 545 1155
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2.2 Study procedures
Neuropsychiatric examinations and interviews
A clinical examination was conducted for each participant including psychiatric, somatic, func-
tional and social tests at an outpatient clinic. If participants declined the examination they were
instead offered an examination in the participant’s home. A semi-structured close informant inter-
view was also performed by telephone and included questions about intellectual function, psychi-
atric symptoms, activity level, dementia symptoms and changes over time. Also, regular follow-
ups have been done for most of the participants (apart from H70 born in 1944, which will be fol-
lowed up for the first time during 2019).
The psychiatric examination was either conducted by a psychiatrist, other medical doctor or a
trained psychiatric research nurse. The medical doctors and psychiatric research nurses were
trained by a psychiatrist and the inter-rater reliability for diagnosing dementia and depression was
estimated to be between good and excellent (kappa-values (κ) between 0.62-1.00 and 0.81-1.00
respectively).
The psychiatric examination and interview was semi-structured including Comprehensive Psy-
chopathological Rating Scale (CPRS)[181], Montgomery-Åsberg Depression Rating Scale (MADRS)[182],
Mini Mental State Examination (MMSE)[183] and rating of symptoms suggesting dementia which
have been described previously[184].
CPRS is a 65-item rating scale measuring psychopathology and is used to asses various differ-
ent psychiatric illnesses. It contains 40 self-reported items and 25 observed items. The scale can
aid in setting diagnoses, follow changes over time and estimate severity of symptoms. Ever-day
language is used in the scale so that it can be used by multiple professions in the psychiatric field
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after little practice. [181]
MADRS is a sub-scale of CPRS and contains ten items for assessing depressive symptoms and
evaluate response to treatment. Each item gives a value between 0-6 which in turn gives a total
score ranging from 0-60. MADRS is often used clinically for classifying severity of depressive
symptoms and follow response to treatment.[182]
Both CPRS and MADRS have been validated for older people[185, 186].
MMSE contains eleven questions that is used to swiftly, but roughly, assess the cognitive status of
the participant. It is widely used clinically for the basal dementia investigation.[183]
Diagnoses
Major depression was diagnosed through DSM-IV by taking items from CPRS representing de-
pressive symptoms. Major depression was diagnosed with the help of nine criteria: at least one
of the core criteria had to be exhibited (depressed mood and/or markedly diminished interest or
pleasure) and at least four of the additional symptoms (significant weight loss or weight gain or
decrease or increase in appetite; insomnia or hypersomnia nearly every day; psychomotor agita-
tion or retardation; fatigue or loss of energy; feelings of worthlessness or excessive or inappro-
priate guilt; diminished ability to think or concentrate, or indecisiveness and recurrent thoughts
about death or suicidal ideation). The symptoms had to be present during the recent month. De-
mentia was not an exclusion criterion. Minor depression was diagnosed through DSM-IV-TR and
required 2-4 of the aforementioned criteria. For this study, “any depression” was defined as hav-
ing either major or minor depression.[187]
Dementia was diagnosed through DSM-IV[188] based on information and testing during the
semi-structured interview. A close informant interview was conducted when possible. Informa-
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tion about dementia status was also gathered from the Swedish Hospital Discharge Register.
2.3 Genetic markers and genotyping
DNA was extracted from blood samples and genotyped using KASPar PCR SNP genotyping sys-
tem according to manufacturer’s protocol (LGC Genomics, Hoddesdon, Herts, UK, http://www.lgcgroup.com/).
The method utilizes two different forward primers, which enables one to distinguish heterozy-
gotes from homozygotes, and a common reverse primer. Genotyping of rs3773976, rs12053868,
rs3773970, rs4687151 and rs9877502 was conducted for this study. The SNPs were chosen based
on that they all had been highly associated with AD disease traits in the two GWASs previously
described[171, 172]. Several SNPs were found in the IL1RAP gene, but some of them showed
high linkage disequilibrium (r2 > 0.8) to the main finding in the study (rs12053868). Hence, the
one’s chosen for this study had a r2 < 0.8[171]. All the genotyped SNPs were in Hardy-Weinberg
equilibrium. None of the SNPs had a minor allele frequency (MAF) <1%. APOE genotyping was
conducted as previously described[189].
2.4 Statistics
Genotype frequencies were compared between cases (i.e. participants that have ever suffered from
a depression) and controls using chi-square test when sufficient number of participants in each
group. Fischer’s exact test was conducted under a dominant genetic model where the rare ho-
mozygote was grouped with heterozygote (i.e. TT and GT/GG for rs3773976, AA and GA/GG for
rs12053868, CC and TC/TT for rs3773970, CC and GC/GG for rs4687151 and GG and AG/AA
for rs9877502) because there were so few carrying the rare homozygote in our study sample. As-
sociation between depression and the genotypes were analyzed using logistic regression analysis
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in two steps under the same dominant genetic model. In the first step, age at first interview was
added as a covariate. In the next step, both age at first interview and APOE ε4-status were added
as covariates. All the above analyses were conducted separately for major depression, minor de-
pression, and a third group “any depression” which means either major or minor depression. Par-
ticipants were labeled as depressed if they ever had fulfilled the criteria for depression at any of
the neuropsychiatric examinations and follow-ups. All the above analyses were in a subsequent
step stratified for gender since we suspected that the effect could differ between the genders. We
also conducted a moderation analysis with an interaction variable (sex×allele) to see whether the
gender stratification was justified.
Association between the genotypes and MADRS-score were analyzed using linear regression in
two steps using the same covariates. The analyses were first conducted for all participants and
then only with depressed participants as well as stratified for gender.
All the statistical analyses were performed in SPSS 24 (IBM: www.ibm.com). Demented par-
ticipants were excluded from all analyses. Consequently, 2715 participants were included in the
statistical analysis (Figure 1).
Since this study is based on a pre-defined hypothesis we refrain from doing a correction for mul-
tiple testing. A Bonferroni correction would also be too conservative since our studies SNPs are
not independent from each other but instead exhibit linkage disequilibrium to some extent. The α
significance level was set to p < 0.05.
No power analysis was conducted since all the data had been gathered at an earlier time and we
would not be able to affect the sample size. However, a candidate gene association study of de-
pression with only 2715 participants is likely to be underpowered.
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802 demented 
11 without evaluation
for dementia
31 without evaluation
for depression
PPSW/H70
n = 1412
H85
n = 517
H95+
n = 475
H70 born 1944 
n = 1155
2715 for analysis
2160 controls555 cases
Minor depression:
445
Major depression:
170
Figure 1: Flowchart of the study group
Genotype were available for 3,559 participants, albeit some of the participants had missing genotype data for a few
of the SNPs due to genotyping errors. Participants without an evaluation for depression (31) or dementia (11) were
excluded. All demented participants were excluded (802), leaving 2,715 participants included in the final analysis:
555 cases wherof 170 had ever fulfilled the criteria for major depression, 445 had ever fulfilled the criteria for minor
depression and 2,160 non-depressed controls
2.5 Ethical consideration
The study has been approved by the Ethics Committee for Medical Research of the University
of Gothenburg (diary number: s 069-01). Informed consent has been obtained from all partici-
pants and/or their relatives in case of dementia. All the data in the database were de-identified and
each participant was instead given a unique serial number. Only a few members of the research
team had access to identify individual participants if more information had to be gathered from
the archive or journals.
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3 Results
Characteristics of the study sample are presented in Table 5. Since the participants have been fol-
lowed over many years, the same person can have been diagnosed with both major and minor de-
pression at different follow-ups and hence appear in both groups, which causes the numbers to not
add up.
Table 5: Characteristics of the Study Sample
Ever any depression (n = 866) Ever major depression (n = 255) Ever minor depression (n = 696) Never depression (n = 2662) Total (n = 3528c)
Gender (female, n and %) 661 (76.3) 202 (79.2) 532 (76.4) 1649 (61.9) 2310 (65.5)
Age at first interview (m and SD) 77.9 (10.4) 76.8 (9.4) 78.1 (10.7) 76.5 (10.1) 76.8 (10.2)
MADRS score (m and SD) 14.4 (7.6) 22.1 (7.4) 12.6 (6.4) 3.6 (3.5) 6.2 (6.7)
Demented (n and %)a 306 (35.5) 85 (33.3) 246 (35.6) 496 (18.7) 802 (22.8)
APO ε4 positive (n and %)b 249 (28.8) 63 (24.7) 208 (29.9) 738 (27.7) 987 (28.0)
a 11 without an evaluation for dementia
b3 without genotyping for APO ε4
c31 without an evaluation for depression and hence not included in this table
3.1 IL1RAP-related SNPs versus depression diagnoses
Associations were found for all the SNPs in the IL1RAP-gene (i.e. rs3773976, rs12053868, rs3773970,
rs4687151) and females with major depression (Table 6, 7, 8 and 9). For all these findings the
common homozygotes were the disease driving genotypes. All these associations were rather
weak, with the strongest being for rs3773970 (OR: 2.01 [95% CI: 1.14-3.56], p=0.016) in the lo-
gistic regression model adjusted for age at first interview and APOE ε4-status (Table 8).
We saw a trend towards significance in other groups: rs12053868 in all participants with major
depression (Table 7); rs3773970 in all participants with major depression, as well as females with
any depression (Table 8); rs4687151 in all participants with major depression (Table 9). For these
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trends the common homozygotes were the disease driving genotypes. Another trend was found
between rs3773976 and men with any depression where carriership of the minor allele appeared
to be disease driving(Table 6).
No association was found for rs9877502 (Table 10).
In the moderation analysis, we saw a trend towards significance for the interaction variable (p=0.052
when including the interaction variable in the logistic regression analysis for rs3773970).
Table 6: Association between IL1RAP rs3773976 and depression status
Gene SNP Any depression Major depression Minor depression
All Female Male All Female Male All Female Male
Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control
N N N N N N N N N N N N N N N N N N
IL1RAP rs3773976 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
TT 438 1691 329 993 109 698 139 1990 109 1213 30 777 347 1782 261 1061 86 721
(80.2) (79.5) (83.1) (79.8) (72.7) (79.0) (83.7) (79.4) (87.9) (80.0) (71.4) (78.4) (78.9) (79.8) (80.8) (80.6) (73.5) (78.7)
GT 105 406 65 236 40 170 26 485 14 287 12 198 90 421 60 241 30 180
(19.2) (19.1) (16.4) (19.0) (26.7) (19.3) (15.7) (19.3) (11.3) (18.9) (28.6) (20.0) (20.5) (18.9) (18.6) (18.3) (25.6) (19.7)
GG 3 30 2 15 1 15 1 32 1 16 0 16 3 30 2 15 1 15
(0.5) (1.4) (0.5) (1.2) (0.7) (1.7) (0.6) (1.3) (0.8) (1.1) (0) (1.6) (0.7) (1.3) (0.6) (1.1) (0.9) (1.6)
Statistical analysis
pa 0.766 0.166 0.088 0.196 0.033 0.339 0.651 1.000 0.234
OR (95% CI)b 1.05 (0.83-1.32) 1.24 (0.92-1.67) 1.43 (0.96-2.12) 1.34 (0.88-2.04) 1.82 (1.04-3.16) 1.46 (0.73-2.91) 1.06 (0.82-1.36) 1.02 (0.75-1.38) 1.34 (0.86-2.08)
pb 1.009 0.153 0.079 0.180 0.035 0.287 0.652 0.919 0.199
OR (95% CI)c 1.04 (0.83-1.32) 1.24 (0.92-1.68) 1.43 (0.96-2.12) 1.34 (0.88-2.05) 1.83 (1.05-3.19) 1.46 (0.73-2.92) 1.06 (0.83-1.36) 1.02 (0.75-1.38) 1.34 (0.86-2.08)
pc 0.717 0.150 0.080 0.176 0.033 0.282 0.646 0.918 0.200
ap-values comparing TT with GT+GG using Fisher’s Exact Test
bOdds ratios with confidence intervals and p-values using logistic regression, comparing TT with GT+GG, with age at first interview as covariate
cOdds ratios with confidence intervals and p-values using logistic regression, comparing TT with GT+GG, with age at first interview and APO ε4-status as covariates
*42 participants without genotype for rs3773976
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Table 7: Association between IL1RAP rs12053868 and depression status
Gene SNP Any depression Major depression Minor depression
All Female Male All Female Male All Female Male
Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control
N N N N N N N N N N N N N N N N N N
IL1RAP rs12053868 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
AA 443 1710 334 1012 109 698 146 2007 114 1232 32 775 347 1806 262 1084 85 722
(81.9) (80.6) (84.8) (81.8) (74.1) (79.0) (86.4) (80.5) (89.8) (81.9) (76.2) (78.4) (80.5) (81.0) (82.4) (82.6) (75.2) (76.6)
GA 96 387 58 212 38 175 23 460 13 257 10 203 82 401 54 216 28 185
(17.7) (18.2) (14.7) (17.1) (25.9) (19.8) (13.6) (18.5) (10.2) (17.1) (23.8) (20.5) (19.0) (18.0) (17.0) (16.5) (24.8) (20.2)
GG 2 24 2 13 0 11 0 26 0 15 0 11 2 24 2 13 0 11
(0.4) (1.1) (0.5) (1.1) (0) (1.2) (0) (1.0) (0) (1.0) (0) (1.1) (0.5) (1.1) (0.6) (1.0) (0) (1.2)
Statistical analysis
pa 0.540 0.195 0.196 0.068 0.028 0.705 0.841 0.935 0.399
OR (95% CI)b 1.09 (0.86-1.39) 1.24 (0.91-1.69) 1.282 (0.86-1.93) 1.55 (0.98-2.43) 1.94 (1.08-3.49) 1.08 (0.52-2.24) 1.03 (0.79-1.33) 1.01 (0.73-1.40) 1.20 (0.76-1.89)
pb 0.490 0.178 0.230 0.058 0.028 0.835 0.839 0.941 0.444
OR (95% CI)c 1.09 (0.86-1.39) 1.24 (0.91-1.69) 1.28 (0.86-1.93) 1.55 (0.99-2.43) 1.95 (1.08-3.52) 1.09 (0.52-2.27) 1.03 (0.79-1.33) 1.01 (0.73-1.39) 1.19 (0.79-1.89)
pc 0.481 0.168 0.229 0.058 0.026 0.817 0.851 0.289 0.448
ap-values comparing AA with GA+GG using Fisher’s Exact Test
bOdds ratios with confidence intervals and p-values using logistic regression, comparing AA with GA+GG, with age at first interview as covariate
cOdds ratios with confidence intervals and p-values using logistic regression, comparing AA with GA+GG, with age at first interview and APO ε4-status as covariates
*53 participants without genotype for rs12053868
Table 8: Association between IL1RAP rs3773970 and depression status
Gene SNP Any depression Major depression Minor depression
All Female Male All Female Male All Female Male
Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control
N N N N N N N N N N N N N N N N N N
IL1RAP rs3773970 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
CC 436 1672 326 987 110 685 139 1969 109 1204 30 765 345 1763 258 1055 87 708
(80.9) (78.4) (83.6) (79.1) (73.8) (77.4) (84.8) (78.5) (88.6) (79.5) (73.2) (77.0) (79.9) (78.7) (81.6) (79.9) (75.0) (77.1)
TC 100 431 62 244 38 187 24 507 13 293 11 214 84 447 56 250 28 197
(18.6) (20.2) (15.9) (19.6) (25.5) (21.1) (14.6) (20.2) (10.6) (19.4) (26.8) (21.6) (19.4) (20.0) (17.7) (18.9) (24.1) (21.5)
TT 3 29 2 16 1 13 1 31 1 17 0 14 3 29 2 16 1 13
(0.6) (1.4) (0.5) (1.3) (0.7) (1.5) (0.6) (1.2) (0.8) (1.1) (0) (1.4) (0.7) (1.3) (0.6) (1.2) (0.9) (1.4)
Statistical analysis
pa 0.215 0.058 0.345 0.061 0.013 0.572 0.652 0.530 0.640
OR (95% CI)b 1.17 (0.92-1.48) 1.34 (0.99-1.81) 1.22 (0.81-1.81) 1.52 (0.98-2.36) 2.00 (1.13-3.54) 1.22 (0.60-2.49) 1.07 (0.83-1.38) 1.12 (0.82-1.53) 1.12 (0.72-1.76)
pb 0.206 0.056 0.341 0.059 0.017 0.581 0.598 0.480 0.612
OR (95% CI)c 1.17 (0.92-1.48) 1.34 (1.00-1.82) 1.22 (0.81-1.82) 1.52 (0.98-2.36) 2.01 (1.14-3.56) 1.23 (0.60-2.51) 1.07 (0.83-1.38) 1.12 (0.82-1.54) 1.12 (0.72-1.76)
pc 0.209 0.054 0.339 0.060 0.016 0.566 0.606 0.481 0.617
ap-values comparing CC with TC+TT using Fisher’s Exact Test
bOdds ratios with confidence intervals and p-values using logistic regression, comparing CC with TC+TT, with age at first interview as covariate
cOdds ratios with confidence intervals and p-values using logistic regression, comparing CC with TC+TT, with age at first interview and APO ε4-status as covariates
*44 participants without genotype for rs3773970
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Table 9: Association between IL1RAP rs4687151 and depression status
Gene SNP Any depression Major depression Minor depression
All Female Male All Female Male All Female Male
Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control
N N N N N N N N N N N N N N N N N N
IL1RAP rs4687151 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
CC 347 1304 257 771 90 533 114 1537 90 938 24 599 272 1379 200 828 72 551
(63.3) (60.8) (64.6) (61.9) (60.0) (59.4) (68.3) (60.9) (72.0) (61.8) (57.1) (59.6) (62.0) (61.2) (62.1) (62.6) (61.5) (59.2)
GC 175 745 123 424 52 321 45 875 30 517 15 358 147 773 108 439 39 334
(31.9) (34.8) (30.9) (34.0) (34.7) (35.8) (26.9) (34.7) (24.0) (34.0) (35.7) (35.6) (33.5) (34.3) (33.5) (33.2) (33.3) (35.9)
GG 26 94 18 51 8 43 8 112 5 64 3 48 20 100 14 55 6 45
(4.7) (4.4) (4.5) (4.1) (5.3) (4.8) (4.8) (4.4) (4.0) (4.2) (7.1) (4.8) (4.6) (4.4) (4.3) (4.2) (5.1) (4.8)
Statistical analysis
χ2a 1.583 1.368 0.129 4.161 5.449 - 0.118 0.042 0.304
pa 0.453 0.505 0.937 0.125 0.066 - 0.943 0.979 0.859
pb 0.302 0.342 0.929 0.059 0.027 0.751 0.789 0.898 0.690
OR (95% CI)c 1.12 (0.92-1.35) 1.12 (0.89-1.42) 1.04 (0.73-1.48) 1.39 (0.99-1.94) 1.59 (1.06-2.39) 1.09 (0.58-2.04) 1.03 (0.84-1.28) 1.02 (0.80-1.31) 1.11 (0.75-1.65)
pc 0.274 0.333 0.845 0.055 0.024 0.799 0.763 0.859 0.606
OR (95% CI)d 1.11 (0.92-1.35) 1.12 (0.89-1.42) 1.04 (0.73-1.48) 1.39 (1.00-1.95) 1.61 (1.07-2.41) 1.1 (0.58-2.06) 1.03 (0.84-1.27) 1.02 (0.80-1.32) 1.11 (0.75-1.65)
pd 0.279 0.331 0.850 0.053 0.022 0.772 0.773 0.852 0.600
a χ2-values and p-values after comparison between all genotypes using chi-square
bp-values comparing CC with GC+GG using Fisher’s Exact Test
cOdds ratios with confidence intervals and p-values using logistic regression, comparing CC with GC+GG, with age at first interview as covariate
dOdds ratios with confidence intervals and p-values using logistic regression, comparing CC with GC+GG, with age at first interview and APO ε4-status as covariates
*24 participants without genotype for rs4687151
Table 10: Association between rs9877502 and depression status
Gene SNP Any depression Major depression Minor depression
All Female Male All Female Male All Female Male
Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control Case Control
N N N N N N N N N N N N N N N N N N
rs9877502 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
GG 206 799 151 464 55 335 60 945 47 568 13 377 169 836 123 492 46 344
(38.6) (37.8) (39.2) (37.7) (37.2) (37.9) (37.0) (38.0) (38.5) (38.0) (32.5) (38.0) (39.3) (37.7) (39.3) (37.8) (39.3) (37.6)
AG 262 1011 189 593 73 418 86 1187 62 720 24 467 207 1066 153 629 54 437
(49.2) (47.8) (49.1) (48.2) (49.3) (47.3) (53.1) (47.8) (50.8) (48.2) (60.0) (47.1) (48.1) (48.1) (48.9) (48.3) (46.2) (47.8)
AA 65 303 45 173 20 130 16 352 13 205 3 147 54 314 37 181 17 133
(12.2) (14.3) (11.7) (14.1) (13.5) (14.7) (9.9) (14.2) (10.7) (13.7) (7.5) (14.8) (12.6) (14.2) (11.8) (13.9) (14.5) (14.6)
Statistical analysis
χ2a 1.638 1.447 0.253 2.945 0.945 3.072 0.908 0.977 0.137
pa 0.441 0.485 0.881 0.229 0.621 0.215 0.635 0.613 0.934
pb 0.727 0.631 0.927 0.867 0.923 0.511 0.551 0.650 0.762
OR (95% CI)c 1.03 (0.85-1.26) 1.07 (0.84-1.35) 1.04 (0.73-1.50) 1.05 (0.75-1.46) 1.02 (0.70-1.49) 1.29 (0.66-2.55) 1.07 (0.86-1.32) 1.07 (0.83-1.37) 1.07 (0.72-1.59)
pc 0.738 0.597 0.822 0.780 0.919 0.459 0.544 0.617 0.747
OR (95% CI)d 1.03 (0.85-1.25) 1.06 (0.84-1.35) 1.04 (0.73-1.50) 1.05 (0.75-1.45) 1.03 (0.70-1.50) 1.30 (0.66-2.56) 1.06 (0.86-1.31) 1.06 (0.82-1.37) 1.07 (0.72-1.59)
pd 0.764 0.613 0.824 0.790 0.885 0.449 0.573 0.649 0.738
a χ2-values and p-values after comparison between all genotypes using chi-square
bp-values comparing GG with AG+AA using Fisher’s Exact Test
cOdds ratios with confidence intervals and p-values using logistic regression, comparing GG with AG+AA, with age at first interview as covariate
dOdds ratios with confidence intervals and p-values using logistic regression, comparing GG with AG+AA, with age at first interview and APO ε4-status as covariates
*69 participants without genotype for rs9877502
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3.2 IL1RAP-related SNPs versus MADRS-score
Significant associations between genotype and MADRS-score were found for rs3773976 and
rs3773970 (Table 11). For rs3773976 a significant association was found for women, both when
including all participants and when including only depressed participants (p = 0.016 and p =
0.036 respectively). The common homozygotes were associated with a higher MADRS-score
and hence more severe depressive symptoms. Among all participants with depression, both men
and women, a significant association was found (p = 0.049), again with the common homozygote
being associated with a higher MADRS-score. Lastly, a significant association was found for all
male participants where carriership of the minor allele was associated with a higher MADRS-
score (p = 0.041). For rs3773970 significant findings were made for all participants and all fe-
males (p = 0.042 and p = 0.011 respectively), with the common homozygotes being associated
with a higher MADRS-score. A trend towards significance was seen in females for rs12053868
and rs4687151. No association was found for rs9877502, but for men with depression a trend to-
wards significance was seen where carriership of the minor allele was associated with a higher
MADRS-score (Table 11).
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Table 11: Association between the SNPs and MADRS-score, demented excluded
All subjects Only depression (Any)
All Female Male All Female Male
IL1RAP rs3773976
MADRS (M and SD) TT 6.1 (6.6) 7.0 (7.1) 4.8 (5.5) 15.6 (7.5) 16.1 (7.7) 14.2 (6.7)
MADRS (M and SD) GT/GG 5.8 (5.9) 5.9 (6.0) 5.6 (5.7) 14.0 (6.3) 14.0 (6.3) 14.1 (6.2)
p-valuea 0.262 0.015 0.042 0.045 0.036 0.920
p-valueb 0.277 0.016 0.041 0.049 0.036 0.953
IL1RAP rs12053868
MADRS (M and SD) AA 6.2 (6.6) 6.9 (7.1) 4.9 (5.5) 15.6 (7.5) 16.1 (7.7) 14.3 (6.7)
MADRS (M and SD) GA/GG 5.7 (6.0) 6.0 (6.1) 5.2 (5.8) 14.3 (6.4) 14.3 (6.5) 14.2 (6.4)
p-valuea 0.116 0.054 0.569 0.097 0.098 0.966
p-valueb 0.130 0.058 0.549 0.105 0.098 0.979
IL1RAP rs3773970
MADRS (M and SD) CC 6.2 (6.6) 6.9 (7.1) 4.9 (5.5) 15.6 (7.5) 16.0 (7.7) 14.2 (6.8)
MADRS (M and SD) TC/TT 5.5 (5.7) 5.8 (5.8) 5.1 (5.5) 14.1 (6.2) 14.4 (6.2) 13.7 (6.3)
p-valuea 0.035 0.010 0.579 0.072 0.115 0.749
p-valueb 0.042 0.011 0.564 0.078 0.112 0.727
IL1RAP rs4687151
MADRS (M and SD) CC 6.2 (6.7) 7.0 (7.2) 4.8 (5.4) 15.6 (7.5) 16.2 (7.7) 13.9 (6.5)
MADRS (M and SD) GC/GG 5.8 (6.2) 6.4 (6.4) 5.1 (5.7) 14.7 (6.9) 14.9 (7.0) 14.4 (6.8)
p-valuea 0.197 0.083 0.486 0.185 0.098 0.702
p-valueb 0.221 0.089 0.463 0.197 0.096 0.729
rs9877502
MADRS (M and SD) GG 6.0 (6.4) 6.9 (6.8) 4.6 (5.3) 15.0 (7.2) 15.7 (7.3) 12.9 (6.6)
MADRS (M and SD) AG/AA 6.0 (6.5) 6.6 (7.0) 5.1 (5.6) 15.5 (7.3) 15.9 (7.6) 14.7 (6.6)
p-valuea 0.922 0.409 0.119 0.372 0.830 0.063
p-valueb 0.841 0.458 0.113 0.368 0.829 0.064
aLinear regression, comparing common homozygote with uncommon homozygote+heterozygote,
with age at first interview as covariate
bLinear regression, comparing common homozygote with uncommon homozygote+heterozygote,
with age at first interview and APO ε4-status as covariates
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4 Discussion
4.1 Major findings
Previous GWASs have found an association between four SNPs (rs3773976, rs12053868, rs3773970
and rs4687151) in the IL1RAP gene, and another SNP (rs9877502) in close vicinity to the IL1RAP
locus and AD disease traits[171, 172]. Since depression and dementia partly share certain path-
omechanisms, such as neurodegeneration, white matter lesions and genetic risk factors, we de-
cided to conduct a candidate gene association study in a merged study sample of four of the lon-
gitudinal gerontological and geriatric population studies in Gothenburg applying a case-control
study design. Our most prominent finding in this study was that the four SNPs located in the
IL1RAP gene were associated with disease status for women with major depression, where the
common homozygote appeared to be the disease driving genotype. Similar results seen for all
these SNPs were not surprising since the four SNPs located in the IL1RAP gene (e.g. rs3773976,
rs12053868, rs3773970, rs4687151) are in relatively high linkage disequilibrium with one an-
other (r2= 0.3-0.7)[171]. We saw a trend towards significance in other groups (i.e. men and women
together and females with any depression), but it is obvious, by looking at the cross-tables, that
these possible associations were driven by females with major depression. Significant associa-
tions between genotype and MADRS-score were found for rs3773976 and rs3773970, and we
saw a trend towards significance for rs12053868 and rs4687151. Again, it seems, by looking at
the table, that females were the disease driving factor for these associations and trends. A more
surprising finding was for rs3773976 (and in some sense rs9877502 although not reaching signif-
icance) in men where carriership of the minor allele was associated with a higher MADRS-score.
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However, we speculate that this could be a spurious finding since men with depression were few
in comparison with women.
It is a known fact that depression involves neuroinflammation[147] (even though its role in the
pathogenesis remains disputed) and elevated levels of several inflammatory substances in the
periphery[89]. Genetic studies of depression have suggested several susceptibility genes related
to inflammation, including IL-1β[98–100]. Our study suggests that genetic variation in IL1RAP,
which constitutes a vital part of the IL1-receptor type 1, could possibly be of importance in the
pathogenesis of LLD - or at least in older women with major depression. The physiological sig-
nificance of ILRAP has been demonstrated in several animal experiments. As the name suggests,
interleukin 1 receptor accessory protein, is just an accessory protein to the receptor. However,
rather than mainly increasing affinity for IL-1, it is an essential part for signal-transducing to take
place when IL-1 binds to its receptor[173]. During the inflammatory response, IL-1 and its bind-
ing to the IL1-receptor type 1 with a functional IL1RAP is crucial for activating the HPA-axis
and increasing of IL-6 levels in the brain and periphery[190, 191]. If we assume that inflamma-
tion is a pivotal factor in depression pathogenesis, and that more inflammation correlates with
more severe depressive symptoms, we can speculate that the major alleles in the four SNPs in the
IL1RAP-locus renders in a more effective signal transmission when IL-1 binds its receptor and
hence offsets a more powerful inflammatory response in these individuals (N.B. this is a very sim-
plistic explanation since inflammatory pathways are known to interact with several other pathways
important for depression pathogenesis[192]). This is in line with previous studies about depres-
sion and inflammation where certain groups of depressed individuals have increased levels of dif-
ferent inflammatory proteins, and that cytokines administered can induce a depressive episode in
otherwise healthy adults[89, 90].
A study investigating these four SNPs in relation to dementia showed the opposite results, where
the minor alleles were associated with AD traits, and the major allele could be seen as protec-
tive against AD[171]. Furthermore, the SNPs minor alleles were associated with both increased
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amyloid burden and decreased microglial activity, suggesting that the minor alleles renders in a
less powerful inflammatory response and decreased amyloid clearance[171]. Indeed, other stud-
ies have shown that IL-1 overexpression reduce amyloid burden while at the same time increas-
ing tau-pathology in rodents[193]. Neuroinflammation has long been seen as pivotal mecha-
nism in AD disease progression, but this assertion is now challenged since neuroinflammation
seems to be beneficial when it comes to increase amyloid clearance and maybe even halt disease
progression[171, 193]. However, this statement is not undisputed.
Although not the main aim of this study, we investigated possible associations between IL1RAP-
related SNPs and dementia in our sample, but no association was found (see Appendix). However,
our sample consisted of participants with different types of dementia and it is possible that these
IL1RAP-related SNPs only are associated with AD.
There is a merging number of studies that present joint mechanisms in disease pathogenesis for
depression and dementia. This study can conclude that it seems like the IL1RAP-locus is of pos-
sible importance for depression, but the disease driving genotype is then probably the one pre-
viously shown to be protective against AD. Earlier studies on partly the same population as in
this study have also shown some distinct and surprising differences between depression and AD.
Studies by Gudmundsson et. al. have shown that depressed females have a distinct CSF-profile
with elevated levels of amyloid beta-42 (Aβ42), neurofilament protein light (NFL) and an in-
creased CSF/serum albumin ratio but no changes in T-tau levels[194, 195]. This differ from the
CSF-profile seen in AD with decreased levels of Aβ42 and elevated levels of T-tau and NFL[196].
As earlier mentioned in the introduction, most of the other studies examining CSF in individuals
with LLD have shown that the CSF-profile is very similar to the AD CSF-profile[145, 146]. The
contradictory results of studies examining CSF in depressed individuals probably reflect the het-
erogeneous nature of depression. Depression, and also LLD, is very much indeed a heterogeneous
disease[8, 41], and certain subtypes of LLD may have a significant overlap with AD, while others
do not.
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In this study we only found an association between the four SNPs in IL1RAP gene and females
with major depression. There are several possible reasons why we could not see any association
among men: To start with, only 1053 men were included in the statistical analysis whereof 153
had been diagnosed with any depression and only 43 with major depression (after excluding indi-
viduals with dementia). Hence, there are limitations in statistical power and we cannot rule out
that a possible association would be seen in a larger study group with more men with depres-
sion. However, genetics and heritability tend to differ between men and women when it comes
to depression. Twin studies have shown that the heritability for depression is lower among men,
29 % for men and 42 % for women, and that genetic risk factors could be sex specific in their
effect[38]. Thus, even though we lack statistical power, we could hypothesize that genetic vari-
ability in IL1RAP could be sex specific in its effect and hence of greater importance for predicting
depression risk in women.
No significant association was found for minor depression, neither for women nor men, even
though this group contained even more study participants. The most intuitive explanation for this
is that minor depression is an even more heterogeneous disease than major depression. To acquire
the diagnosis minor depression, in our study sample, participants have to fulfill one of the core
criteria (depressed mood and/or markedly diminished interest or pleasure) and two of the addi-
tional criteria, which could be anything from “weight gain and increased appetite” to “psychomo-
tor retardation and diminished ability to think”. The diagnosis will be the same but the clinical
picture could be very different. It is plausible to speculate that there are different pathomecha-
nisms and genetic risk factors involved in these vastly different disease presentations. In addition,
among older people, a chronic mental disorder often underlies a major depressive episode, which
is linked to a more vulnerable personality and a greater familial heredity, while minor depression
often tend to be a reaction to life stressors (i.e. illnesses, death of spouse, loneliness etc.)[197].
However, some people argue that major and minor depression are in a single continuum with the
same genetic risk factors, and the heritability for minor depression have been expected to be 37%
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in one study[198]. Under these conditions, an association should have been found for minor de-
pression, or at least for the total group “any depression”, and our main finding in depressed fe-
males could be dismissed as a spurious finding.
4.2 Strengths and weaknesses
A strength of this study is the population-based design, which make our study sample represen-
tative of the whole population. In addition, the study group were very homogeneous, consisting
mostly of white northern Europeans which increases the chances of finding a possible association.
Another strength was the thorough examination of each participant, by either a psychiatrist or a
trained psychiatric nurse, and that there have been several follow-ups for most of the participants
with high response rates. This is very important for being able to detect all participants with a
predisposition for LLD since depression often goes with remissions and relapses.
This study had several limitations. Firstly, our sample size of 2715 participants in the statistical
analysis is rather small which is reflected in our significant findings that would not survive a cor-
rection for multiple testing. This does not rule out that there is an association between IL1RAP
and LLD, but it is still possible that this could be a spurious finding. Another weakness is that
women were over-represented in this study, since the PPSW cohort consisted solely of women.
There were too few men in this study, and a possible association could have been missed. Lastly,
it is difficult to differentiate between depression with a debut later in life and recurrent depres-
sion in late life, which is a confounding factor when conducting studies on LLD, and much of the
depression seen in the older population is partly caused by chronic pain, neurological disorders,
poly-pharmacy and various different somatic illnesses which we did not take into account in this
study.
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4.3 Future directions
First off, future studies will require much larger study samples since the effect sizes are really
small when it comes to depression. To find and establish a solid association with some certainty
requires tens of thousands of participants. The whole research field struggles with this issue since
it is extremely costly and demanding to include that many participants. One way to possibly by-
pass this obstacle would be to purify the group of participants with depression. Because of the
heterogeneous nature of depression it is highly likely that the genetic risk factors will be different.
One approach would be to only include depressed with similar main symptoms and with no other
comorbidities, and maybe also only include women since the heritability is much higher. Then the
chance will increase that they share similar genetic risk factors. This is of course a tradeoff, we
would increase our power, but we will miss out on most of depressed individuals.
Another possibility would be to distinguish LLD from recurrent depression in late-life, since there
are some striking differences between LLD and EOD, probably with different risk factors[9].
When studying genes that have been implicated in Alzheimer’s disease it is presumably better
to have a study sample consisting solely of depression with a first debut later in life. However,
we did not have any reliable information about depressive episodes at younger age in our study
sample. Most people recall earlier episodes of sadness during life and it is hard for the assessor to
determine if this represents true depression or just normal rational sadness.
Lastly, it would be interesting to follow all the study participants longitudinally and to see who
eventually develops dementia and who do not. As earlier mentioned there could be subtypes of
LLD that lies closer to dementia than others. We speculate that the findings for IL1RAP could be
different between these two subgroups.
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4.4 Conclusions
In this population-based cohort we found modestly significant associations between four SNPs
in the IL1RAP gene and females with major depression as well as with MADRS-score for two of
the SNPs. The effect size and study sample were small and replication in larger study cohort is
required to strengthen this association. However, there is now some evidence that genetic varia-
tion in the IL1RAP gene, which have been implicated in AD, could be of importance in LLD as
well. Both LLD and AD are in desperate need for new treatments and alternative pathways like
IL1/IL1RAP may prove to be of importance in the future.
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5 Populärvetenskaplig sammanfattning
Genetisk variation i genen IL1RAP och dess koppling till depression hos äldre
Depression kan drabba människor i alla åldrar. Vissa drabbas bara en gång medan det för andra
kan återkomma genom hela livet. En särskilt utsatt grupp i samhället är äldre människor som ofta
lider av depressiva symptom. Ofta förklaras det med att man som gammal drabbas av sjukdomar
och ensamhet. En meningsfull tillvaro och en god fysisk hälsa är i allra högsta grad viktigt för det
psykiska välbefinnandet - men det kan inte ensamt förklara varför vissa drabbas av depression.
Forskning har visat att en del av svaren till varför depression uppstår går att hitta i våra gener.
Även om vi människor delar 99,5% av vårt genetiska material finns det små subtila skillnader i
den genetiska koden som gör varje människa unik. Dessa skillnader påverkar hur vi ser ut men
också vår risk att insjukna i olika sjukdomar. När det gäller depression påverkar varje enskild
genetisk variation ganska lite men sammantaget kan flera av dessa variationer sänka vår tröskel
för att insjukna i depression. Man har tidigare hittat kopplingar mellan depression och variation i
gener som kodar för signalsubstanser, tillväxtfaktorer, inflammationssubstanser mm.
Hos äldre människor kan det ibland vara svårt att särskilja på demens och depression. I viss mån
delar sjukdomarna symptom såsom koncentrationssvårigheter, förlorat intresse för aktiviteter och
intresseområden samt social isolering. Det finns också belägg för att sjukdomarna delar vissa
sjukdomsmekanismer och genetiska riskfaktorer. Inflammatoriska processer i hjärnan har visat
sig ha betydelse för både depression och demens. Nyligen har forskare hittat belägg för att genetisk
variation i genen som kodar för interleukin 1 receptor accessory protein (IL1RAP) kan påverka
risken för att utveckla Alzheimers sjukdom. Denna gen är viktig för inflammatoriska signaler-
ingsvägar. Denna gen har aldrig undersökts i relation till depression hos äldre. Därför har vi i
denna studie undersökt denna gen hos 2715 studiedeltagare som ska representera Göteborgs äl-
dre befolkning.
Vi fann ett samband mellan genetisk variation i IL1RAP och kvinnor med svår depression. Vi
hittade inget samband för män och för personer med lättare depression. Våra resultat var gan-
ska svaga och studien skulle behöva upprepas i en studie med fler deltagare, där också fler män
inkluderas, för att kunna påvisa ett tydligare samband. Trots detta finns det nu ett visst belägg för
att IL1RAP skulle kunna vara viktig när det gäller risken att utveckla svår depression hos äldre
kvinnor. Genetisk forskning av depression är viktigt för att förstå sjukdomsmekanismer ytterligare
och kan på sikt öppna för nya behandlingsmetoder.
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A Appendix
Table 12: Association between the SNPs and dementia status
Dementia No Dementia Chi-square Logistic regressiona
Gene: SNP N (%) N (%) χ2 p-value OR p-value
IL1RAP: rs3773976
TT 629 (80.3) 2129 (79.6)
GT 149 (19.0) 511 (19.1) 1.994 0.369 1.082 0.511
GG 5 (0.6) 33 (1.2)
IL1RAP rs12053868
AA 635 (80.1) 2153 (80.9)
GA 152 (19.2) 483 (18.1) 0.717 0.699 1.008 0.948
GG 6 (0.8) 26 (1.0)
IL1RAP rs3773970
CC 609 (77.4) 2108 (78.9)
TC 172 (21.9) 531 (19.9) 2.400 0.301 1.066 0.574
TT 6 (0.8) 32 (1.2)
IL1RAP rs4687151
CC 496 (62.3) 1651 (61.4)
GC 271 (34.0) 920 (34.2) 1.053 0.591 1.084 0.406
GG 29 (3.6) 120 (4.5)
rs9877502
GG 298 (38.6) 1005 (38.0)
AG 364 (47.2) 1273 (48.1) 0.225 0.894 1.037 0.711
AA 110 (14.2) 368 (13.9)
aLogistic regression comparing common homozygote with uncommon homozygote
+ heterozygote, with age at first interview, APO ε4-status and gender as covariates.
